We analyse the new funds created in Spain in the biotechnology sector during the first half of 2018. In this case, we will study the company Inveready and the alliance between Asabys Partners and Banco Sabadell.
Get in touch with our experts.
We analyse the new funds created in Spain in the biotechnology sector during the first half of 2018. In this case, we will study the company Inveready and the alliance between Asabys Partners and Banco Sabadell.
Inveready Technology Investment Group, a Catalan venture capital firm, is a venture capital firm specialising in providing value to early-stage technology companies. According to ASCRI it is one of the leading funds in Spain and in 2017 they were awarded the prize for the best asset management firm in Spain. With six investment funds. Inveready invests in technology companies with high growth potential and innovative business models. Inveready has extensive experience in different areas, with more than 80 leading portfolio companies in their respective markets.
Inveready has six investment vehicles with €92 million under management. The funds have invested in more than 80 companies since 2008.
Since we are analysing the new funds that have emerged within the biotech sector, it is worth noting that the average investment in Catalan companies belonging to this sector in 2017 was €3.4M.
With this year's fund, it would be the third investment vehicle in the biotech sector. The fund, called Biotech III, would be the Barcelona-based fund manager's ninth and would have a size of €25m.
Asabys Partners, based in Barcelona, is a professional investment firm that works closely with entrepreneurs to build healthcare and innovation companies with technologies and products designed to transform people's lives and provide disruptive solutions to today's healthcare challenges. It specialises in biotech, medtech and healthcare innovation start-ups.
Asabys has recently signed a partnership with Banco Sabadell to launch its first specialised health sciences vehicle, Sabadell Asabys Health Innovation Fund, with a target size of €60M to invest in early stage drug development companies, medical devices and digital applications in Spain, the UK and Israel.
It is worth noting that Banco Sabadell's participation is proof of its continued commitment to investing in the healthcare sector, acting as a benchmark investor in this fund, along with Asabys, recently launched by Sanfeliu, former co-founder/partner of Ysios Capital.
| Company | Inverter | Country | Amount | Date |
| Abac Therapeutics | Caixa Capital Risk
Pontifax Global Health Science Fund Debiopharm Innovation Fund
|
Spain | 16M€ | 15/02/2018 |
| BDi Biotechnology | Inveready
Dyadic International |
Spain | 3,9M€ | 4/01/2018 |
| Bionure | Alta Life Science | USA. USA. | 4M€ | 17/05/2018 |
| Proteodesign | Caixa Capital Risk
Business Angels |
Spain | 1,7M€ | 28/02/2018 |
New funds in March: Artá, Black Toro, Nekko, Benavent and Trea Direct Lending
New funds in February: Nexxus, Torreal, TowerBrook, Peninsula and Providence
If you are looking for investors, want to buy or sell your company or finance your R&D&I project, contact our Corporate Finance experts.
If you are looking for investors, want to buy or sell your company or finance your R&D&I project, contact our Corporate Finance experts.
EN 
ES